Research programme: mirror-image oligonucleotides - NOXXON

Drug Profile

Research programme: mirror-image oligonucleotides - NOXXON

Alternative Names: NOX-A50; NOX-D14; NOX-D19; NOX-D20; NOX-D21; NOX-F37; NOX-G15; NOX-G16

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NOXXON Pharma AG
  • Class Nucleotide aptamers; Oligonucleotides
  • Mechanism of Action Complement C5 inhibitors; Complement C5a inhibitors; HMGA1b protein inhibitors; Vasopressin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Pneumonia
  • No development reported Cancer; Inflammation
  • Discontinued Heart failure; Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Germany (Parenteral)
  • 04 Jan 2017 Spiegelmers® technology licensed to Aptarion worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top